文献速递核素与放射性配体治疗肿瘤 PET/CT

转移性去势抵抗性前列腺癌患者中递增剂量177Lu-EB-PSMA放射性配体治疗

177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer.
PubMed 文献 · J Nucl Med · 2020-05-01

本研究将转移性去势抵抗性前列腺癌患者随机分为三组,分别接受1.18±0.09 GBq、2.12±0.19 GBq和3.52±0.58 GBq的177Lu-EB-PSMA-617治疗,最多3个周期、间隔8周。B组和C组前列腺特异性抗原疾病控制率高于A组(P=0.007),B组与C组间无相关性;C组2例(25.0%)发生4级血小板减少。作者认为2.12 GBq剂量似乎安全且足以治疗肿瘤,需扩大样本量进一步研究。

要点

  • B组(70%)和C组(75%)的前列腺特异性抗原疾病控制率高于A组(10%)(P=0.007)。
  • C组2例(25.0%)患者发生4级血小板减少,未观察到严重肾脏或肝脏副作用。
  • 作者认为2.12 GBq的177Lu-EB-PSMA剂量似乎安全且足以治疗肿瘤。

核心结论

  • 本研究显示2.12 GBq剂量的177Lu-EB-PSMA在肿瘤治疗中似乎安全且足够。
  • 需要增加患者数量进一步研究。

研究设计与样本

  • 经机构审查委员会批准并签署知情同意后,患者被随机分为3组。
  • A组(n=10)接受1.18±0.09 GBq的177Lu-EB-PSMA治疗。
  • B组(n=10)接受2.12±0.19 GBq的177Lu-EB-PSMA治疗。
  • C组(n=8)接受3.52±0.58 GBq的177Lu-EB-PSMA治疗。
  • 合格患者接受最多3个周期的177Lu-EB-PSMA治疗,间隔8周。

主要发现

  • 因疾病进展或骨髓抑制,A组10例中4例、B组10例中5例、C组8例中5例按计划完成3个周期治疗。
  • 前列腺特异性抗原反应与治疗剂量相关,B组(70%)和C组(75%)的前列腺特异性抗原疾病控制率高于A组(10%)(P=0.007),但B组与C组间未发现相关性。
  • 68Ga-PSMA PET/CT显示所有治疗组均有反应,但3组间无显著差异。
  • 血液学毒性研究发现B组和C组血小板下降较A组更明显,C组2例(25.0%)患者发生4级血小板减少。
  • 未观察到严重的肾脏或肝脏副作用。

局限性

  • 需要增加患者数量进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This study was designed to assess the safety and therapeutic response to 177Lu-labeled Evans blue-modified prostate-specific membrane antigen (PSMA) 617 (EB-PSMA-617) treatment with escalating doses in patients with metastatic castration-resistant prostate cancer. Methods: With institutional review board approval and informed consent, patients were randomly divided into 3 groups: group A (n = 10) was treated with a 1.18 ± 0.09 GBq dose of 177Lu-EB-PSMA. Group B (n = 10) was treated with a 2.12 ± 0.19 GBq dose of 177Lu-EB-PSMA. Group C (n = 8) was treated with a 3.52 ± 0.58 GBq dose of 177Lu-EB-PSMA. Eligible patients received up to 3 cycles of 177Lu-EB-PSMA therapy, at 8-wk intervals. Results: Because of disease progression or bone marrow suppression, 4 of 10, 5 of 10, and 5 of 8 patients completed 3 cycles of therapy as planned in groups A, B, and C, respectively. The prostate-specific antigen response was correlated with treatment dose, and the prostate-specific antigen disease control rates were higher in groups B (70%) and C (75%) than in group A (10%) (P = 0.007), but no correlation between groups B and C was found. 68Ga-PSMA PET/CT showed a response in all treatment groups; however, there was no significant difference among the 3 groups. A hematologic toxicity study found that platelets decreased more in groups B and C than in group A and that grade 4 thrombocytopenia occurred in 2 (25.0%) patients in group C. No serious nephritic or hepatic side effects were observed. Conclusion: This study demonstrated that a 2.12-GBq dose of 177Lu-EB-PSMA seems to be safe and adequate in tumor treatment. Further investigations with an increased number of patients are warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zang J, Liu Q, Sui H, et al. 177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2020. PMID: 32358086. doi:10.2967/jnumed.120.242263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。